Outcome Of Treatment Of Prostate Cancer at Sohag University Hospital Between 2017 to 2021

• Conditions: Prostate Cancer

• Registration Number: NCT05382182
• Lead Sponsor: Sohag University

Brief Summary

Worldwide, prostate cancer is the most commonly diagnosed male cancer and the fourth leading cause of cancer death in men. Risk stratification is according to cancer stage, Gleason score, and PSA level .

Definitive treatment of localized disease ( low and favorable intermediate risk) includes watchful waiting , active surveillance , radiation therapy , radical prostatectomy and cryotherapy .Primary treatment of unfavorable intermediate risk , high risk localized disease and locally advanced prostate cancer , includes both radical prostatectomy (RP) and EBRT + long-term androgen deprivation therapy (ADT) .Treatment options of metastatic prostate cancer include pain medications, bisphosphonates, hormonal treatment, chemotherapy, radiotherapy, immunotherapy, focused radiation, and other targeted therapies .

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2022-05
• Study First Submitted: 2022-05-15
• Study First Submitted QC: 2022-05-15
• Last Update Submitted: 2022-05-15
• Study First Posted: 2022-05-19
• Last Update Posted: 2022-05-19
• Study Start: 2022-06-01
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 100

Inclusion Criteria

• Patients at age of 18 years old and above.
• All stages and grades of prostate cancer.
• Epithelial types of prostate cancer.

Read More

Exclusion Criteria

• Age below 18 years old.
• Presence of other malignancies.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall survival	6 months	Overall survival defined as the time from the date of diagnosis to the last date seen .
progression free survival	6 months	Progression-free survival defined as the length of time during and after the treatment of cancer that a patient lives with the disease but it does not get worse.
disease free survival	6 months	Disease free survival defined as the time from the end of treatment to the date of first relapse .

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt